Esperion Therapeutics (ESPR) Misses Q4 EPS by 7c ; Provides Outlook

Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of $0.22, $0.07 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $168.45 million versus the consensus estimate of $168.28 million.

2026 Financial Outlook

The Company expects full year 2026 operating expenses to be in the range of $225 million to $255 million, including approximately $15 million in non-cash expenses related to stock compensation.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
• Bain Capital Exited Flash Memory Maker Kioxia, Executive Says - Bloomberg
• First Majestic raises 2026 output guidance after Q2 silver, gold gains